AstraZeneca’s IMFINZI® (durvalumab) Approved in the US for Comprehensive Treatment of Resectable Non-Small Cell Lung Cancer AstraZeneca has announced that IMFINZI® (durvalumab), in combination with chemotherapy, has received approval from the US Food and Drug Administration (FDA) for the treatment…
Agendia is pleased to announce that it has achieved certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three of its products: the MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray, and the MammaPrint® and BluePrint® NGS…
BioNTech SE (Nasdaq: BNTX) today revealed top-line results from their Phase 3 clinical trial evaluating a combined mRNA vaccine candidate against influenza and COVID-19 in healthy adults aged 18-64. This combination vaccine includes Pfizer’s mRNA-based influenza candidate and the companies’…
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Medigene AG (FSE: MDG1, Prime Standard) have announced a three-year strategic partnership. The collaboration aims to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs)…
ILiAD Biotechnologies, a biotech company developing the most advanced next-generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the company to its Fierce 15 2024 list, recognizing ILiAD as one of the most promising and innovative biotechnology companies…
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899) involving patients with unresectable stage III or IV melanoma whose…
Today, Eisai Co. Ltd. presented new findings on lecanemab-irmb (branded as LEQEMBI® in the U.S.) at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia and online. This dual-acting anti-amyloid beta (Aβ) protofibril antibody is designed for early Alzheimer’s disease…
Lario Therapeutics Secures $6M Grant from Michael J. Fox Foundation for Parkinson’s Research Lario Therapeutics, a biopharmaceutical company focused on pioneering precision medicines for neurological and epileptic disorders, has announced it has been awarded a $6 million USD grant from…
Ionis Pharmaceuticals today revealed that it has finalized enrollment in its pivotal trial evaluating zilganersen (ION373), an investigational RNA-targeted therapy aimed at treating children and adults with Alexander disease (AxD), a rare, progressive, and ultimately fatal neurological disorder. The trial’s…
WHO and UNICEF have unveiled new national immunization coverage estimates (WUENIC), offering the most comprehensive view of global vaccination trends for 13 diseases. The findings present both progress and pressing challenges. In 2023, 108 million children worldwide received three doses…
Neurocrine Biosciences has introduced a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the leading VMAT2 inhibitor for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease. This new INGREZZA® SPRINKLE (valbenazine) formulation is now available through the same…
A prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been named a constituent of the FTSE4Good Index Series. This recognition, marking the fourth year in a row, highlights the company’s exceptional performance in sustainability. The FTSE4Good…